Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Q4 2024 vs. Q3 2024
How the institutions holding Damora Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 10 | 10 | 0 |
| Shares | 128.6K | 142.1K | +13.4K (+10.4%) |
| Value | $1.56M | $660.7K | −$902.2K (−57.7%) |
New holders (3)
Institutions that held Damora Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Squarepoint Ops LLC | 12,701 | $59.1K | 0.00% |
| JPMorgan Chase & Co | 100 | $466 | 0.00% |
| SBI Securities Co., Ltd. | 18 | $84 | 0.00% |
Sold out (3)
Institutions that held Damora Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Tower Research Capital LLC (TRC) | 346 | $4.20K |
| Harbour Investments, Inc. | 8 | $97 |
| Danske Bank A/S | 7 | $85 |